Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia.
The efficacy of tricyclic antidepressants and monoamine oxidase inhibitors for the treatment of agoraphobia and other panic disorders is reviewed with an emphasis on controlled prospective studies. After methodological biases are taken into account, there is strong evidence that antidepressants suppress panic attacks. This effect is not dependent on the presence of concomitant depressive symptoms. The clinical issues of dosage, delay in response, and relapse with discontinuation of treatment are also reviewed.
D000379:Agoraphobia / Q000188:drug therapy* / Q000523:psychology; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010200:Panic / Q000187:drug effects; D010624:Phenelzine / Q000627:therapeutic use; D010698:Phobic Disorders / Q000188:drug therapy*
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D002997:Clomipramine; D010624:Phenelzine; D007099:Imipramine; D003975:Diazepam